Abstract: Embodiments of the present application provide a method, apparatus, and electronic device for eliminating distortion of a distorted image. Side information components of a distorted image are generated. The distorted image is resulted from image processing on an original image. Side information components represent distortion features of the distorted image with respect to original image. Distorted image color components of the distorted image and the side information components are input into a pre-established convolutional neural network model for convolution filtering to obtain distortion-eliminated image color components. The convolutional neural network model is obtained through training based on a preset training set. The training set comprises original sample images, distorted image color components of multiple distorted images corresponding to each of the original sample images, and side information components of each of the distorted images.

Abstract: Provided herein are macrophages engineered for treating fibrosis and ameliorating the effects of fibrotic lesions in various organs and tissues. Certain embodiments are directed to genetically-engineered macrophages capable of treating fibrosis or reducing fibrotic lesions. In certain aspects macrophages can be genetically-engineered to (1) target extracelluar matrix (ECM) or components thereof, (2) enhance degradation of ECM, or (3) target ECM and enhance degradation of ECM. Further provided is a cellular therapy product comprising a genetically-engineered macrophage comprising at least one of a recombinant targeting protein and a recombinant catalytic enzyme. Further provided is a method of treating an individual for fibrosis comprising administering the cellular therapy product.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: A bit rate control method device obtains a bit rate control mode and coding control parameters of a current short period in a long period, determines a frame-level coding parameter of the current short period, and transmits the frame-level coding parameter to an encoder. Second bit stream information is obtained and statistical analysis is performed which includes complexity information of the current video frame, the number of the encoded bits in the current short period, and coding quality information of the current short period, so as to encode a video frame of the next, adjacent short period by calculating a frame-level coding parameter of the next, adjacent short period. By the present solution, the storage space is allocated reasonably under the condition that the image satisfies a certain quality.

Abstract: When performing an inter predictive encoding on any image frame x is required, a reference image frame is determined for image x; image x is a P-frame image or a B-frame image; for each reference image frame, following processes are respectively performed: whether resolution of a reference image frame is the same as resolution of image x is determined; if resolution of the reference image frame is different from resolution of image x, resolution of reference image frame is adjusted to be the same as resolution of image x; if resolution of each reference image frame is the same as resolution of image x, inter predictive encoding is performed on image x based on each reference image frame.

Abstract: Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.

Abstract: A bit rate control method and device is disclosed. The method comprises: obtaining a bit rate control mode and coding control parameters of a current short period in a long period, determining a frame-level coding parameter of the current short period, and transmitting the frame-level coding parameter to an encoder; obtaining second bit stream information sent by the encoder; performing statistical analysis according to the second bit stream information to obtain statistical information including complexity information of the current video frame, the number of the encoded bits in the current short period, and coding quality information of the current short period; when the long period has not ended and if the current short period has ended, obtaining a period length of the current short period, the preset bit rate control parameters and the statistical information, and determining an average bit rate.

Abstract: Systems, devices and methods are provided for video encoding and decoding. An example method includes: analyzing one or more input images; obtaining a background image from the one or more input images; encoding the background image to obtain a background frame; decoding the background frame to obtain a reconstructed image of the background frame; obtaining a first image from the one or more input images; encoding at least partially the first image to obtain a refreshment frame based at least in part on a difference between the first image and the reconstructed image of the background frame; obtaining a second image from the one or more input images; encoding at least partially the second image to obtain a common frame; and generating a video bit stream based at least in part on the background frame, the refreshment frame and the common frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: When performing an inter predictive encoding on any image frame x is required, a reference image frame is determined for image x; image x is a P-frame image or a B-frame image; for each reference image frame, following processes are respectively performed: whether resolution of a reference image frame is the same as resolution of image x is determined; if resolution of the reference image frame is different from resolution of image x, resolution of reference image frame is adjusted to be the same as resolution of image x; if resolution of each reference image frame is the same as resolution of image x, inter predictive encoding is performed on image x based on each reference image frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: Systems, devices and methods are provided for video encoding and decoding. An example method includes: analyzing one or more input images; obtaining a background image from the one or more input images; encoding the background image to obtain a background frame; decoding the background frame to obtain a reconstructed image of the background frame; obtaining a first image from the one or more input images; encoding at least partially the first image to obtain a refreshment frame based at least in part on a difference between the first image and the reconstructed image of the background frame; obtaining a second image from the one or more input images; encoding at least partially the second image to obtain a common frame; and generating a video bit stream based at least in part on the background frame, the refreshment frame and the common frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.

Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.